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Abstract
Using data collected of a large population-based cohort
study, we studied the association between anthropometric
factors and the risk of pancreatic cancer. Furthermore, we
investigated whether these associations differ among micro-
scopically confirmed pancreatic cancer (MCPC) cases and
non-MCPC (NMCPC) cases. The Netherlands Cohort Study
on Diet and Cancer started in 1986 (120,852 men and women)
and uses the case-cohort methodology. After 13.3 years of
follow-up, 446 pancreatic cancer cases (of which 65% was
microscopically confirmed) and 4,774 subcohort members
were available for analysis. The multivariable incidence rate
ratio of MCPC of men was 1.10 per increment of 1 kgm2
(95% confidence interval, 1.04-1.18). Women had a rate ratio
of MCPC of 1.08 (95% confidence interval, 1.03-1.13). Obese
men [body mass index (BMI) z30 kgm2] had a 2.6-fold
increased risk of MCPC compared with men with BMI 23 to
25 kgm2. For women, this increase in risk was 1.7-fold.
Change in BMI between age 20 years and baseline was also
associated with MCPC in both men and women. In men and
women, none of these associations were observed for
NMCPC, with the exception of the increased risk for
pancreatic cancer in obese men. We observed statistically
significant associations between both BMI, gain in BMI,
and pancreatic cancer risk. These associations are observed
only in MCPC and not in NMCPC. If MCPC and NMCPC
had been considered as one group, the reported associations
would not have been detected. These findings stress the need
to evaluate heterogeneity among pancreatic cancer cases in
etiologic studies. (Cancer Epidemiol Biomarkers Prev
2007;16(7):1449–54)
Introduction
Although pancreatic cancer does not rank among the most
common cancers in the Western world, it is the sixth most
common cause of cancer death in Europe (1) and fourth in the
United States (2). Its prognosis is one of the most dismal of all
cancers and in both Europe and the United States (3), 5-year
survival rates of only 4% to 5% for all tumors and <1% for
nonresectable tumors (4) have been reported. To date, no
effective means of early detection, prevention, or treatment are
available.
Few risk factors have been implicated in the etiology of
pancreatic cancer, with cigarette smoking being the most con-
sistent (5), accounting for f25% of the incidence (5, 6). Other
potentially modifiable lifestyle factors, including body mass
index (BMI) or obesity, may influence the risk of pancreatic
cancer but thus far studies have produced inconsistent results.
Results from both case-control and cohort studies showed
positive associations between BMI, or obesity, and pancreatic
cancer (7, 8), whereas other studies found no association (7, 9).
Among studies reporting a positive association, some pre-
sented evidence of this association among both men and
women (7, 8), whereas others among men alone (7). One
possible explanation for these inconsistent findings, besides
other issues of bias, may be differences among studies in the
diagnostic criteria used to define ‘‘caseness.’’ In epidemiologic
studies of pancreatic cancer, contrary to other forms of cancer,
microscopic (or cytohistologic) confirmation often lacks for
more than 30% to 40% of all cases. In the United States,
pancreatic cancer cases without confirmation represent one
fourth of the total number of pancreatic cancer cases (10),
whereas in certain areas and demographic groups this figure
may even be higher (11). In Europe, populations of pancreatic
cancer cases having <50% microscopic verification are ob-
served in Czech Republic, Ireland, Italy, Malta, Poland,
Portugal, Slovakia, Spain, and the United Kingdom (12).
Cases without pathologic confirmation (but with strong
clinical evidence supporting the diagnosis) are often included
in epidemiologic studies (13), but may reflect different
subtypes of pancreatic cancer or even nonpancreatic cancer.
The aim of the present study, therefore, is 2-fold. Using the
data collected in a large population-based cohort study, we
study the association between anthropometric factors and
the risk of pancreatic cancer. Furthermore, we will investigate
whether these associations differ among microscopically
confirmed pancreatic cancer (MCPC) cases and non-MCPC
(NMCPC) cases.
Materials and Methods
The Cohort. The Netherlands Cohort Study is an ongoing
prospective cohort study on diet and cancer among 58,279 men
and 62,573 women who were ages 55 to 69 years at base-
line. Baseline exposure data were collected by means of a self-
administered questionnaire in September 1986.
The study was designed as a case-cohort study: Cases
arising from the cohort provide numerator information for
the calculation of cancer incidence rates, whereas the
accumulated person-years in the entire cohort (denominator
information for the rates) are estimated using a random
sample of 5,000 from the cohort (subcohort). This subcohort
was sampled directly after the identification of all cohort
members and has been followed up biennially for vital status
information. Further details on The Netherlands Cohort
Study on Diet and Cancer study design have been reported
elsewhere (14).
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All prevalent cancer cases, other than skin tumors, at
baseline (75 men and 151 women) were excluded from the
subcohort. The remaining 4,774 subcohort members (2,336 men
and 2,438 women) were available for analyses.
Follow-up. The present analyses are restricted to a follow-
up of 13.3 years, up to December 1999. Exocrine pancreatic
cancer cases (ICD-O-3 code C25, excluding C25.4; n = 447) in
the cohort were identified through record linkage to the
Netherlands cancer registries and the nationwide pathology
register PALGA (15). After excluding endocrine subtypes
based on histology (islet cell carcinoma, n = 1), 446 pancreatic
cancers were available for analyses. Of all exocrine pancreatic
cancers, 65% was microscopically confirmed (MCPC, n = 290),
whereas confirmation was missing for 35% (NMCPC, n = 156).
The diagnosis of the latter group was made by the treating
clinician and based on clinical symptoms, physical examina-
tion and imaging results, and abstracted and recorded by a
trained tumor registrar (16).
Only two subcohort members were lost to follow-up after
13.3 years and completeness of cancer follow-up has been
estimated to be at least 96%.
Questionnaire Data. The collected questionnaire data on
anthropometry (self-reported height, weight, weight at age 20
years) and other potential risk factors from subcohort and
pancreatic cancer cases were key entered twice by research
assistants who were blinded with respect to subcohort/case
status to minimize observer bias in coding and interpretation
of the data.
Rate ratios (RR) for height and weight were presented per
centimeter and kilogram, respectively. BMI was calculated by
dividing weight (kg) by height squared (m2). RRs are
presented per 1 kgm2 increment for BMI at baseline, BMI
at age 20 years, and BMI gain between age 20 years and
baseline. Additional to the analyses with continuous variables,
height, weight, BMI, BMI at age 20 years, and BMI gain since
age 20 years were also analyzed as categorical variables.
Information on BMI at baseline was missing for 4% subcohort;
BMI at age 20 years and BMI gain information was missing for
18% of the subcohort.
Energy intake (kcal/d) was calculated from the food
frequency questionnaire using the computerized Dutch food
composition table. Further details are given elsewhere (17).
Statistical Analysis. Incidence RRs and corresponding 95%
confidence intervals (95% CI) for pancreatic cancer were
estimated in age-adjusted and multivariable case-cohort
analyses using the Cox proportional hazards model processed
with the Stata statistical software package (release 9; Stata
Corporation). SEs were estimated using the robust Huber-
White sandwich estimator to account for additional variance
introduced by sampling from the cohort (18). The proportional
hazards assumption was tested using the scaled Schoenfeld
residuals (19). In case the proportional hazards assumption
was not met, time-varying variables were included for those
variables that contributed to the violation of the proportional
hazards assumption. In none of the cases the main determinant
of interest (any of the measures of anthropometry) violated the
assumption.
Tests for dose-response trends in risk of pancreatic cancer
were assessed by fitting ordinal exposure variables as
continuous terms. The following variables were considered
as confounders: age at baseline, sex, cigarette smoking (current
smoking (yes/no), number of years of smoking, and number of
cigarettes smoked per day), and history of diabetes (yes/no)
and hypertension (yes/no). All models containing gain in BMI
since the age of 20 years were adjusted for BMI at age 20 years.
The results are presented for men and women separately as the
sex-specific effect estimates differed from the models including
both sexes. Two-sided P values are reported throughout the
article.
Results
The distributions of determinants and potential confounders
(stratified for gender) are presented in Table 1. Among men,
only age at diagnosis (69.3 versus 71.2 years) and the medical
history of hypertension (18.5% versus 32.4%) were statistically
significantly lower for MCPC compared with NMCPC. BMI
was higher, although not significantly, among MCPC com-
pared with NMCPC. The percentage of current smokers and
medical history of diabetes was higher among cases, both male
MCPC and NMCPC, compared with male subcohort members.
History of gallstones was more present among male subcohort
members compared with pancreatic cancer cases (5.1% versus
2.6% in MCPC and 4.1% in NMCPC).
Female NMCPC were older at baseline and diagnosis,
weighed less at baseline and had a lower BMI at age 20 years,
and had more often a medical history of high blood pressure
and gallstones compared with MCPC. Also in women, more
pancreatic cancer cases smoked at baseline compared with
subcohort members (30.1% and 24.7% for MCPC and NMCPC,
respectively, versus 20.9%).
Table 2 presents the RRs for pancreatic cancer according
to height, weight, BMI, BMI at age 20 years, and change in BMI
between age 20 years and baseline in men. When considering
MCPC and NMCPC as one group, none of the determinants
(as continuous variables) showed a statistically significant
association with pancreatic cancer. BMI at baseline showed
an increased risk for the upper category (BMI z30 kgm2;
RR, 2.69; 95% CI, 1.47-4.92) compared with the reference
category (BMI 23-25 kgm2). Also, change in BMI since age 20
years shows a significantly increased risk for the upper
category (change z8 kgm2; RR, 2.21; 95% CI, 1.09-4.49)
compared with the reference category (change 0-4 kgm2).
In the MCPC subgroup weight, BMI at baseline and change
in BMI were all significantly associated with pancreatic
cancer: weight, RR, 1.02 (95% CI, 1.01-1.04); BMI at baseline,
RR, 1.10 (95% CI, 1.04-1.18); change in BMI, RR, 1.12 (95% CI,
1.04-1.21). P values for trend were found statistically signifi-
cant for the categorized variables of weight, BMI at base-
line, and change in BMI. For the NMCPC subgroup, none of
the associations were significant, although the risk estimates
for third, fourth, and fifth BMI quintiles were comparable
with those in MCPC. For NMCPC, a RR of 2.62 (95% CI,
1.29-5.31) was observed when comparing the first to the
second quintile (reference) of BMI. Because this low BMI could
be due to subclinical disease, we excluded the first 2 and
5 years of follow-up. The results, however, did not change
(RR, 2.23; 95% CI, 1.08-4.63 and RR, 2.45; 95% CI, 1.14-5.23 for
the data set excluding the first 2 and 5 years of follow-up,
respectively).
Table 3 presents the RRs for pancreatic cancer according to
height, weight, BMI, BMI at age 20 years, and change in BMI
between age 20 years and baseline in women. When
considering MCPC and NMCPC as one group, height, weight
at baseline, and change in BMI since age 20 years were
significantly associated with pancreatic cancer (P values for
trend of categorized height, weight at baseline, and change in
BMI were significant as well).
The association with height was also observed among
NMCPC subgroup (RR, 1.05; 95% CI, 1.01-1.09) but not in
MCPC. Conversely, weight and change in BMI since age 20
years were associated with pancreatic cancer among MCPC
(RR, 1.03; 95% CI, 1.01-1.04 and RR, 1.08; 95% CI, 1.02-1.13,
respectively) but not with NMCPC. BMI at baseline was
associated with pancreatic cancer among MCPC (RR, 1.08; 95%
CI, 1.03-1.13), but not in NMCPC or the total group of
pancreatic cancer.
The results of our analyses did not change for men or
women after excluding the first 2 and 5 years of follow-up
(results not shown).
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Discussion
In this large prospective study, we found evidence that BMI
and BMI change since age 20 years are positively associated
with MCPC, both in men and women. These associations were
not observed in the NMCPC subgroup, which constituted 35%
of our total population of pancreatic cancer cases. Moreover, in
the analyses combining MCPC and NMCPC, no association of
BMI at baseline with pancreatic cancer was found (except
when comparing the upper category of BMI with the reference
category).
For men, a RR of 1.10 per increment of 1 kgm2 (95% CI,
1.04-1.18) of MCPC was found for BMI at baseline. Obese men
(BMI z30 kgm2) had a 2.6-fold increased risk compared with
men with BMI 23 to 25 kgm2. For women, this increase in risk
was 1.7-fold. Women had a RR of 1.08 (95% CI, 1.03-1.13) of
MCPC for BMI at baseline (per kgm2 increment). For every
unit increase in BMI since the age of 20 years, which translates
for a male of height 1.75 m to a gain of F3 kg, a relative
increase in risk of MCPC was found of 12%. For women, a
relative increase in risk of MCPC was found of 8% for every
unit increase in BMI (i.e., female of 1.65 m, a gain of F2.5 kg).
In case preclinical pancreatic cancer was present at baseline,
this would conceivably have resulted in weight loss and due to
this an underestimation of the effect of BMI. Excluding the first
2 or 5 years of follow-up did not change our results, however.
In a meta-analysis, comprising six case-control studies and
eight cohort studies (published before 2004; ref. 7), the
summary relative risk per unit increase in BMI was 1.02 per
increment of 1 kgm2 (95% CI, 1.01-1.03); the relative risk for
obese subjects (BMI z30 kgm2) compared with subjects with
normal weight (BMI 22 kgm2) was 1.19 (95% CI, 1.10-1.29).
In a recent meta-analysis by Larsson et al. (20), including
21 prospective studies on BMI and pancreatic risk published
from 1966 to November 2006, an estimated summary RR of
pancreatic cancer was reported per 5 kg/m2 increase in BMI of
1.12 (95% CI, 1.06-1.17; Pheterogeneity = 0.13) in men and women
combined, 1.16 (95% CI, 1.05-1.28; Pheterogeneity = 0.001) in men,
and 1.10 (95% CI, 1.02-1.19; Pheterogeneity = 0.12) in women. The
RRs presented in these two meta-analyses are lower compared
with the results of the present study in both the total group of
pancreatic cancer cases and the MCPC subgroup. Although
some studies did report the proportions of NMCPC (8, 21-23),
ranging from 20% (23) to almost 100% (21), most studies in the
meta-analyses did not distinguish between MCPC and
NMCPC or report on the proportion of NMCPC in the total
case set. In the studies that reported the proportion of
NMCPC, all but one (23) showed increased risks, but only
statistically significant for men in one study (21). Differences
across studies may, at least in part, be due to different
populations with differing proportions of NMCPC in the total
case sets.
Obesity may be mechanistically linked to pancreatic cancer
because of its association with abnormal glucose metabolism,
including insulin resistance, hyperinsulinemia, and impaired
glucose tolerance (24-26). Experimental studies showed that
insulin has growth-promoting and mitogenic effects on pan-
creatic cancer cells (27). Also, in epidemiologic studies, positive
associations between postload plasma glucose concentration,
exposure to higher insulin concentrations, insulin resistance,
and pancreatic cancer risk have been reported (28-30).
In our study, we found no statistically significant association
between height and pancreatic cancer risk in men. In women,
an association was observed among all pancreatic cancer and
NMCPC (RR, 1.02; 95% CI, 1.00-1.05 and RR, 1.05; 95% CI, 1.01-
1.09, respectively) but not in MCPC. Previously, four cohort
studies reported on height and the risk of pancreatic cancer:
Two found a statistically significant association (8, 9), whereas
two other studies did not (28, 31). Adult height has also been
found to be associated with an increased risk of some other
cancers, including the breast, prostate, thyroid, colon, and
endometrium (32, 33), and may be a proxy for exposure to
circulating growth factor levels during adolescence or child-
hood, genetic predisposition, or prenatal exposures. Because
Table 1. Baseline characteristics of subjects stratified for gender
Men Women
Pancreatic cancer cases Subcohort
(n = 2,336)
Pancreatic cancer cases Subcohort
(n = 2,438)
MCPC
(n = 157)
NMCPC
(n = 74)
P MC-
NMCPC
MCPC
(n = 133)
NMCPC
(n = 82)
P MC-
NMCPC
Age, y (SD) 61.8 (3.9) 62.8 (4.3) 0.085 61.3 (4.2) 61.8 (4.5) 64.1 (3.6) <0.001 61.5 (4.3)
Age at diagnosis, y (SD) 69.3 (4.7) 71.2 (5.4) 0.007 — 69.8 (5.2) 73.3 (5.4) <0.001 —
Person-time, y (SD) 2,538 (1,276) 2,867 (1,315) 0.071 4,271 (1,164) 2,729 (1,305) 3,175 (1,279) 0.015 4,553 (860)
Height, cm (SD) 176.3 (6.4) 176.8 (7.1) 0.585 176.4 (6.7) 165.7 (6.0) 166.8 (6.5) 0.224 165.1 (6.2)
Weight, kg (SD) 79.7 (10.6) 77.2 (10.6) 0.099 77.9 (9.5) 71.4 (10.8) 69.7 (9.7) 0.264 68.5 (10.3)
Weight at age 20 y, kg (SD) 68.2 (7.9) 67.7 (9.1) 0.715 67.8 (8.3) 60.1 (10.4) 57.3 (7.3) 0.031 58.2 (7.9)
BMI, kg m2 (SD) 25.6 (2.8) 24.8 (3.5) 0.102 25.0 (2.6) 26.0 (3.6) 25.1 (3.4) 0.082 25.1 (3.6)
BMI age 20 y, kgm2 (SD) 21.9 (2.2) 21.7 (2.6) 0.475 21.7 (2.4) 21.9 (3.7) 20.7 (3.0) 0.013 21.4 (2.8)
Change in BMI, kgm2 (SD) 3.8 (3.0) 3.1 (3.9) 0.253 3.3 (3.0) 4.2 (4.2) 4.4 (4.1) 0.698 3.7 (3.7)
Smoking
Current smokers (%) 48.7 46.0 0.694 36.7 30.1 24.7 0.395 20.9
n cigarettes/d (SD) 16.5 (10.0) 18.6 (14.2) 0.228 17.1 (10.6) 11.0 (7.0) 13.9 (9.6) 0.096 11.6 (8.3)
n years smoked (SD) 35.4 (12.9) 36.8 (9.8) 0.410 33.8 (11.9) 28.9 (12.4) 29.4 (12.4) 0.843 28.0 (12.4)
Alcohol, g/d (SD) 17.3 (19.5) 18.6 (18.5) 0.645 15.0 (16.8) 7.0 (10.0) 7.5 (12.3) 0.057 5.9 (9.5)
Energy-intake, kcal/d (SD) 2,199 (466) 2,073 (482) 0.649 2,165 (510) 1,684 (381) 1,707 (441) 0.707 1,686 (398)
Vegetable intake, g/d (SD) 196 (95) 186 (80.0) 0.435 192 (85) 214 (82) 207 (85) 0.578 196 (81)
Fruit intake, g/d (SD) 144 (106) 165 (144) 0.233 154 (114) 186 (99) 203 (120) 0.284 196 (121)
Medical history of
Diabetes (%) 7.6 10.8 0.424 3.5 6.0 2.4 0.227* 4.2
High blood pressure (%) 18.5 32.4 0.019 23.1 25.6 39.0 0.037 29.4
Gallstones (%) 2.6 4.1 0.533 5.1 12.8 24.4 0.029 13.8
Cholecystectomy (%) 3.2 2.7 0.842 4.5 13.5 19.5 0.243 13.3
Educational level
Low (%) 46.0 46.4 47.8 60.7 55.2 58.8
Medium (%) 33.1 30.4 0.907 34.3 33.0 41.4 0.471 33.0
High (%) 20.9 23.2 17.9 6.3 3.5 8.3
*Cell count <5.
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weight and height were self-reported, as in most other large-
scale epidemiologic studies, misclassification cannot be ruled
out. Systematic underestimation of weight and overestimation
of height have been previously reported (34). It is noted that
the higher the measured BMI, the greater the underestimation
of weight and overestimation of height (34). This tendency,
if present in our study, could have led to an underestimation
of the effect of BMI.
The strengths of this study include the prospective design,
large sample size, and detailed information on potential risk
factors of pancreatic cancer. The prospective design precluded
recall bias and the need to use next-of-kin respondents (which
is often needed in the case-control when studying the highly
fatal pancreatic cancer). Moreover, because exposure data were
collected before the diagnosis of any cases of pancreatic cancer,
any error in recall (nondifferential misclassification) would
have attenuated rather than exaggerated a true association.
Differential follow-up is unlikely to have made a material
contribution to these findings, since follow-up in our cohort
was high.
In the present study, we stratified for microscopic confir-
mation, as the lack of such confirmation may be a source of
misclassification of disease status. In 1996, Silverman et al. (35)
addressed this issue deeper by reanalyzing their data on the
association of smoking and pancreatic cancer risk and
reevaluating their case series recruited in the years 1986 to
1989 (5). The case series from the original study was
subdivided according to both microscopically confirmation of
the diagnosis and the degree of diagnostic certainty [classified
as ‘‘likely’’ if at least one of the following criteria was satisfied:
(a) a pancreatic mass was known by radiographic visualization
or surgery, with a compatible histologic diagnosis; (b) a
pancreatic mass was known by surgery and, although a biopsy
specimen was not obtained, it appeared to be malignant due
to either visible hepatic metastasis or local extension; or (c) a
pancreatic mass was known by radiographic visualization,
although a biopsy specimen was not obtained, and there were
supporting clinical signs, symptoms, and course (e.g., rapid
death)]. They reported an odds ratio for ‘‘ever smoker’’ of
1.8 (95% CI, 1.4-2.4) for MCPC considered ‘‘likely’’ to have had
Table 2. RRs of pancreatic cancer, with 95% CI, according to anthropometry (men only)
Variable Categorical
mean
PYs in
subcohort
All pancreatic cancer MCPC NMCPC
No.
cases
RR*
(95% CI)
RR
c
(95% CI)
No.
cases
RR*
(95% CI)
RR
c
(95% CI)
No.
cases
RR*
(95% CI)
RR
c
(95% CI)
Height at baseline (cm)
<170
b
166.1 3,910 34 1 1 23 1 1 11 1 1
170-<175 171.9 6,952 46 0.77 (0.48-1.23) 0.68 (0.41-1.12) 29 0.71 (0.40-1.25) 0.55 (0.30-1.00) 17 0.91 (0.42-1.98) 1.07 (0.44-2.60)
175-<180 176.7 8,182 75 1.09 (0.71-1.68) 1.14 (0.72-1.82) 55 1.17 (0.70-1.95) 1.10 (0.65-1.87) 20 0.94 (0.45-1.98) 1.25 (0.53-2.95)
180-<185 181.7 5,632 42 0.87 (0.54-1.40) 0.80 (0.48-1.34) 31 0.94 (0.54-1.65) 0.79 (0.44-1.42) 11 0.73 (0.31-1.73) 0.86 (0.33-2.27)
z185 188.0 3,371 26 0.92 (0.53-1.58) 0.99 (0.56-1.75) 14 0.71 (0.36-1.41) 0.71 (0.36-1.42) 12 1.42 (0.61-3.30) 1.82 (0.69-4.81)
P trend 0.947 0.715 0.868 0.896 0.701 0.435
Continuous,
per cm
28,046 223 1.00 (0.98-1.02) 1.01 (0.99-1.03) 152 1.00 (0.98-1.02) 1.00 (0.97-1.02) 71 1.01 (0.99-1.05) 1.02 (0.98-1.06)
Weight at baseline (kg)
<75x 68.5 10,272 74 1 1 47 1 1 27 1 1
75-<80 76.4 5,553 47 1.16 (0.79-1.71) 1.16 (0.76-1.76) 35 1.37 (0.87-2.15) 1.41 (0.87-2.28) 12 0.80 (0.40-1.60) 0.73 (0.34-1.58)
80-<85 81.4 5,860 46 1.09 (0.74-1.60) 1.13 (0.75-1.70) 30 1.12 (0.70-1.79) 1.23 (0.75-2.02) 16 1.04 (0.55-1.95) 0.95 (0.48-1.86)
85-<90 86.2 3,120 21 0.95 (0.57-1.58) 0.92 (0.53-1.59) 13 0.91 (0.48-1.71) 0.96 (0.49-1.88) 8 1.01 (0.45-2.26) 0.82 (0.33-2.05)
z90 95.1 3,436 36 1.49 (0.97-2.27) 1.55 (0.99-2.45) 29 1.89 (1.16-3.06) 2.07 (1.24-3.47) 7 0.79 (0.34-1.85) 0.77 (0.32-1.88)
P trend 0.206 0.182 0.090 0.047 0.796 0.605
Continuous,
per kg
28,270 224 1.01 (0.99-1.03) 1.01 (0.99-1.03) 154 1.02 (1.01-1.04) 1.02 (1.01-1.04) 70 0.99 (0.96-1.02) 0.99 (0.96-1.02)
BMI at baseline (kgm2)
<23 21.5 5,484 44 1.11 (0.75-1.66) 1.10 (0.72-1.69) 21 0.67 (0.40-1.14) 0.66 (0.38-1.16) 23 2.63 (1.36-5.09) 2.62 (1.29-5.31)
23-<25x 24.1 9,088 67 1 1 52 1 1 15 1 1
25-<27 25.9 7,430 50 0.91 (0.62-1.34) 0.93 (0.61-1.39) 35 0.82 (0.53-1.28) 0.90 (0.57-1.44) 15 1.22 (0.59-2.53) 0.98 (0.44-2.16)
27-<30 28.1 4,672 39 1.14 (0.75-1.73) 1.17 (0.75-1.81) 29 1.10 (0.69-1.77) 1.20 (0.73-1.97) 10 1.26 (0.56-2.85) 1.12 (0.47-2.63)
z30 31.5 1,166 20 2.54 (1.47-4.41) 2.69 (1.47-4.92) 14 2.23 (1.19-4.18) 2.57 (1.30-5.10) 6 3.36 (1.27-8.92) 2.87 (0.94-8.70)
P trend 0.139 0.141 0.018 0.008 0.517 0.312
Continuous,
per kgm-2
27,838 220 1.05 (0.99-1.11) 1.05 (0.99-1.12) 151 1.09 (1.02-1.16) 1.10 (1.04-1.18) 69 0.96 (0.85-1.10) 0.94 (0.81-1.08)
BMI at age 20 y (kgm2)
<20
b
18.5 4,360 35 1 1 22 1 1 13 1 1
20-<21 20.5 4,095 26 0.78 (0.46-1.32) 0.80 (0.46-1.40) 19 0.92 (0.49-1.73) 0.93 (0.48-1.80) 7 0.55 (0.22-1.41) 0.62 (0.23-1.66)
21-<23 22.0 7,745 60 0.97 (0.62-1.50) 0.99 (0.62-1.59) 42 1.08 (0.64-1.85) 1.16 (0.67-2.04) 18 0.78 (0.38-1.62) 0.73 (0.32-1.64)
z23 24.6 6,168 52 1.07 (0.68-1.69) 1.07 (0.67-1.73) 40 1.32 (0.77-2.26) 1.33 (0.76-2.34) 12 0.67 (0.30-1.48) 0.68 (0.29-1.63)
P trend 0.541 0.562 0.239 0.226 0.485 0.480
Continuous,
per kgm2
22,368 173 1.03 (0.96-1.09) 1.03 (0.96-1.10) 123 1.04 (0.97-1.11) 1.04 (0.97-1.11) 50 0.99 (0.87-1.13) 1.00 (0.87-1.15)
Change in BMI since age 20 yx (kgm2)
<0 1.8 1,824 14 0.97 (0.53-1.79) 0.99 (0.53-1.85) 8 0.76 (0.34-1.68) 0.74 (0.33-1.65) 6 1.54 (0.64-3.73) 1.84 (0.74-4.56)
0-<4
b
2.1 12,150 84 1 1 56 1 1 28 1 1
4-<8 5.7 7,103 60 1.30 (0.89-1.90) 1.34 (0.90-1.99) 50 1.75 (1.15-2.67) 1.89 (1.22-2.94) 10 0.54 (0.25-1.20) 0.45 (0.18-1.08)
z8 10.0 1,231 15 2.17 (1.13-4.15) 2.21 (1.09-4.49) 9 2.10 (0.97-4.55) 2.56 (1.14-5.72) 6 0.93 (0.61-6.15) 1.28 (0.32-5.18)
P trend 0.042 0.052 0.011 0.001 0.617 0.288
Continuous,
per kgm2
22,308 173 1.06 (0.98-1.14) 1.07 (0.99-1.15) 123 1.10 (1.02-1.18) 1.12 (1.04-1.21) 50 1.02 (0.99-1.05) 0.92 (0.76-1.11)
Abbreviation: PYs, person-years.
*Adjusted for age (continuous).
cAdjusted for age (continuous), smoking (current smoker: yes/no; number of cigarettes smoked per day: continuous; number of years smoked: continuous), history of
diabetes (yes/no), and history of hypertension (yes/no).
bReference category.
xBMI at age 20 y was included in all models for BMI change.
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pancreatic cancer, 1.3 (95% CI, 0.6-2.8) for NMCPC considered
likely to have had pancreatic cancer, and 1.0 (95% CI, 0.4-2.4)
for cases considered ‘‘unlikely’’ to have had pancreatic cancer.
These findings illustrate that when case series include
NMCPC, even if they are considered likely, the effect estimate
may be attenuated toward the null. Restriction to (likely) cases
with microscopic confirmation will generate the most valid
estimates of risk, which is of importance especially when
considering risk factors that exert small to modest effects, such
as BMI.
In our study, the effects of BMI and change of BMI since age
20 years in men would not have been detected without the
stratification on microscopic verification (the effect of BMI
since age 20 years in women was weaker in all pancreatic
cancer compared with MCPC). Conversely, in women, a
statistically significant association of height at baseline was
found in all pancreatic cancer cases, but not in MCPC. Most of
the previous studies on the association of BMI and pancreatic
cancer did not distinguish between MCPC and NMCPC nor
reported the contribution of NMCPC to the total population of
pancreatic cancer cases. This may, in part, explain differences
found across studies.
Cases without pathologic confirmation (but with strong
clinical evidence supporting the diagnosis) may reflect differ-
ent subtypes of pancreatic cancer or even nonpancreatic cancer.
Whenever these subtypes or nonpancreatic cancers are not,
or more strongly, associated with the determinant of interest
compared with MCPC, the effect estimates will affected. The
practice of including NMCPC in epidemiologic studies is in our
view sound provided that risk estimates are computed and
reported across strata of microscopic verification, or diagnostic
certainty, to exclude heterogeneity.
In summary, we observed associations between both BMI
and gain in BMI and pancreatic cancer risk. Another con-
sequence of the increasing epidemic of obesity in the Western
society may thus be an increasing incidence of pancreatic
cancer in the coming years. However, these associations are
observed only in MCPC and not in NMCPC. These findings
stress the need to evaluate heterogeneity among pancreatic
cancer cases.
Table 3. RRs of pancreatic cancer, with 95% CIs, according to anthropometry (women only)
Variable Categorical
mean
PYs in
subcohort
All pancreatic cancer MCPC NMCPC
No.
cases
RR*
(95% CI)
RR
c
(95% CI)
No.
cases
RR*
(95% CI)
RR
c
(95% CI)
No.
cases
RR*
(95% CI)
RR
c
(95% CI)
Height at baseline (cm)
<160
b
155.7 5,156 27 1 1 19 1 1 8 1 1
160-<165 161.9 7,715 39 0.95 (0.57-1.57) 0.93 (0.56-1.57) 28 0.98 (0.54-1.77) 0.90 (0.49-1.65) 11 0.89 (0.35-2.24) 0.98 (0.38-2.50)
165-<170 166.7 10,400 86 1.63 (1.04-2.55) 1.60 (1.02-2.53) 48 1.27 (0.73-2.18) 1.22 (0.70-2.11) 38 2.45 (1.13-5.32) 2.42 (1.11-5.28)
170-<175 171.4 5,289 36 1.35 (0.80-2.27) 1.40 (0.83-2.37) 22 1.13 (0.60-2.12) 1.13 (0.60-2.13) 14 1.88 (0.77-4.56) 2.06 (0.84-5.06)
z175 177.0 2,248 17 1.52 (0.80-2.86) 1.32 (0.67-2.60) 10 1.22 (0.55-2.67) 0.98 (0.41-2.33) 7 2.21 (0.79-6.21) 2.18 (0.73-6.48)
P trend 0.027 0.044 0.424 0.563 0.007 0.008
Continuous,
per cm
30,809 205 1.03 (1.00-1.05) 1.02 (1.00-1.05) 127 1.01 (0.99-1.04) 1.01 (0.98-1.04) 78 1.05 (1.01-1.09) 1.05 (1.01-1.09)
Weight at baseline (kg)
<65
b
58.5 11,082 59 1 1 36 1 1 23 1 1
65-<70 66.6 6,482 42 1.19 (0.79-1.80) 1.23 (0.81-1.88) 24 1.13 (0.66-1.92) 1.20 (0.70-2.05) 18 1.30 (0.69-2.44) 1.28 (0.66-2.46)
70-<75 71.4 5,687 39 1.29 (0.85-1.97) 1.30 (0.84-1.99) 24 1.30 (0.77-2.21) 1.31 (0.75-2.27) 15 1.29 (0.66-2.50) 1.28 (0.68-2.44)
75-<80 76.2 3,582 31 1.62 (1.03-2.55) 1.58 (0.99-2.52) 20 1.73 (0.98-3.03) 1.77 (1.00-3.17) 11 1.47 (0.71-3.06) 1.37 (0.65-2.89)
z80 86.1 4,721 39 1.59 (1.04-2.43) 1.64 (1.07-2.52) 26 1.72 (1.02-2.89) 1.88 (1.09-3.22) 13 1.39 (0.70-2.79) 1.34 (0.68-2.61)
P trend 0.011 0.010 0.014 0.009 0.262 0.323
Continuous,
per kg
31,555 210 1.02 (1.01-1.03) 1.02 (1.01-1.03) 130 1.03 (1.01-1.04) 1.03 (1.01-1.04) 80 1.01 (0.99-1.03) 1.01 (0.99-1.03)
BMI at baseline (kgm2)
<23 21.3 8,307 46 1.03 (0.67-1.57) 1.02 (0.66-1.58) 23 0.82 (0.47-1.44) 0.82 (0.46-1.45) 23 1.35 (0.71-2.55) 1.35 (0.70-2.57)
23-<25
b
24.0 8,328 45 1 1 28 1 1 17 1 1
25-<27 26.0 6,326 55 1.60 (1.06-2.42) 1.69 (1.11-2.58) 36 1.70 (1.02-2.83) 1.91 (1.14-3.23) 19 1.43 (0.73-2.80) 1.38 (0.70-2.70)
27-<30 28.3 4,869 38 1.42 (0.90-2.22) 1.41 (0.89-2.25) 25 1.54 (0.88-2.67) 1.55 (0.87-2.78) 13 1.24 (0.60-2.59) 1.27 (0.61-2.64)
z30 32.6 2,827 19 1.27 (0.73-2.22) 1.31 (0.74-2.31) 14 1.49 (0.77-2.87) 1.72 (0.87-3.39) 5 0.91 (0.33-2.52) 0.78 (0.28-2.14)
P trend 0.064 0.052 0.006 0.002 0.736 0.539
Continuous,
per kgm2
30,657 203 1.04 (1.00-1.08) 1.04 (1.00-1.08) 126 1.07 (1.02-1.11) 1.08 (1.03-1.13) 77 1.00 (0.94-1.07) 0.99 (0.93-1.05)
BMI at age 20 y (kgm2)
<20
b
18.4 8,542 65 1 1 37 1 1 28 1 1
20-<21 20.5 3,966 27 0.87 (0.55-1.40) 0.93 (0.58-1.51) 13 0.75 (0.39-1.43) 0.81 (0.42-1.57) 14 1.04 (0.54-2.02) 1.06 (0.54-2.08)
21-<23 22.0 8,164 42 0.67 (0.45-1.00) 0.69 (0.46-1.04) 28 0.78 (0.47-1.30) 0.80 (0.48-1.33) 14 0.53 (0.27-1.01) 0.55 (0.28-1.06)
z23 24.9 7,020 52 1.00 (0.68-1.47) 0.97 (0.66-1.44) 37 1.21 (0.76-1.95) 1.21 (0.74-1.96) 15 0.71 (0.37-1.35) 0.66 (0.34-1.30)
P trend 0.606 0.535 0.548 0.590 0.108 0.089
Continuous,
per kgm2
27,691 186 1.02 (0.95-1.09) 1.02 (0.95-1.09) 115 1.07 (1.00-1.14) 1.07 (1.00-1.14) 71 1.03 (1.00-1.06) 1.03 (1.00-1.05)
Change in BMI since age 20 yx (kgm2)
<0 2.5 3,104 15 0.66 (0.36-1.19) 0.67 (0.37-1.21) 9 0.50 (0.23-1.09) 0.50 (0.23-1.11) 6 0.96 (0.38-2.40) 0.95 (0.38-2.38)
0-<4
b
2.2 12,012 76 1 1 50 1 1 26 1 1
4-<8 5.7 9,287 63 1.09 (0.77-1.53) 1.08 (0.75-1.55) 38 1.09 (0.71-1.67) 1.13 (0.71-1.78) 25 1.07 (0.61-1.85) 1.02 (0.59-1.78)
z8 10.3 3,187 31 1.63 (1.06-2.52) 1.72 (1.11-2.67) 18 1.58 (0.91-2.74) 1.81 (1.03-3.18) 13 1.55 (0.77-3.10) 1.40 (0.70-2.78)
P trend 0.007 0.004 0.011 0.004 0.290 0.394
Continuous,
per kgm2
27,590 185 1.05 (1.01-1.10) 1.05 (1.01-1.10) 115 1.07 (1.01-1.12) 1.08 (1.02-1.13) 70 1.02 (0.95-1.10) 1.01 (0.94-1.08)
*Adjusted for age (continuous).
cAdjusted for age (continuous), smoking (current smoker: yes/no; number of cigarettes smoked per day: continuous; number of years smoked: continuous), history of
diabetes (yes/no), and history of hypertension (yes/no).
bReference category.
xBMI at age 20 y was included in all models for BMI change.
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